United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

a a h pharmaceuticals ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

fresenius kabi ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

Israel - English - Ministry of Health

merck sharp & dohme israel ltd - cilastatin sodium; imipenem as monohydrate - powder for solution for infusion - cilastatin sodium 500 mg/vial; imipenem as monohydrate 500 mg/vial - imipenem and enzyme inhibitor - imipenem and enzyme inhibitor - 1.1 lower respiratory tract infectionstienam for intravenous use is indicated for the treatment of lower respiratory tract infections caused by susceptible strains of staphylococcus aureus (penicillinase-producing isolates), acinetobacter species, enterobacter species, escherichia coli, haemophilus influenzae, haemophilus parainfluenzae, klebsiella species, serratia marcescens.1.2 urinary tract infections (complicated and uncomplicated) tienam is indicated for the treatment of urinary tract infections (complicated and uncomplicated) caused by susceptible strains of enterococcus faecalis, staphylococcus aureus (penicillinase-producing isolates), enterobacter species, escherichia coli, klebsiella species, morganella morganii, proteus vulgaris, providencia rettgeri, pseudomonas aeruginosa.1.3 intra-abdominal infections tienam is indicated for the treatment of intra-abdominal infections caused by susceptible strains of enterococcus faecalis, staphylococcus aureus (penicillinase-producing isolates), staphylococcu

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

organon pharma (uk) ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme (uk) ltd - cilastatin sodium; imipenem monohydrate - powder for solution for infusion - 500mg ; 500mg

Jordan - English - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

شركة أدوية الحكمة - hikma pharmaceuticals - imipenem (as monohydrate) 500 mg, cilastatin (as sodium) 500 mg - (as monohydrate) 500 mg, (as sodium) 500 mg

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - imipenem anhydrous (unii: q20im7he75) (imipenem anhydrous - unii:q20im7he75), cilastatin (unii: 141a6amn38) (cilastatin - unii:141a6amn38), relebactam anhydrous (unii: 1oqf7tt3pf) (relebactam anhydrous - unii:1oqf7tt3pf) - recarbrio™ is indicated for the treatment of patients 18 years of age and older with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia, caused by the following susceptible gram-negative microorganisms: acinetobacter calcoaceticus-baumannii complex, enterobacter cloacae , escherichia coli , haemophilus influenzae , klebsiella aerogenes, klebsiella oxytoca, klebsiella pneumoniae, pseudomonas aeruginosa, and serratia marcescens. recarbrio is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cuti), including pyelonephritis, caused by the following susceptible gram-negative microorganisms: enterobacter cloacae , escherichia coli , klebsiella aerogenes, klebsiella pneumoniae, and pseudomonas aeruginosa . approval of this indication is based on limited clinical safety and efficacy data for recarbrio [see clinical studies (14.2)] . recarbrio is indicated in patients

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

fresenius kabi sa-nv - cilastatin sodium 530 mg - eq. cilastatin 500 mg; imipenem monohydrate 530 mg - eq. imipenem 500 mg - powder for solution for infusion - imipenem and enzyme inhibitor

Australia - English - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - ganciclovir sodium, quantity: 546 mg (equivalent: ganciclovir, qty 500 mg) - injection, powder for - excipient ingredients: - ganciclovir sxp (ganciclovir) administered as the iv infusion is indicated for the palliative treatment of confirmed sight-threatening cytomegalovirus (cmv) disease in aids and other severely immunocompromised individuals. it is indicated for the treatment of confirmed cmv pneumonitis in bone marrow transplant patients. it is also indicated for the prophylaxis of cmv infection and disease following bone marrow and solid organ transplantation in patients at risk of cmv disease.,note: ganciclovir sxp (ganciclovir) is not indicated for congenital or neonatal cmv disease; nor for the treatment of cmv infection in non-immunocompromised individuals.

Kenya - English - Pharmacy and Poisons Board

imipenem and cilastatin for injection usp - powder for injection - imipenem 500mg & cilastatin sodium 500mg - imipenem and enzyme inhibitor